ArjunVasantBalarMD

Genitourinary Oncology, Hematologic Oncology

Associate Professor, Medicine, New York University School of Medicine; Director - Genitourinary Medical Oncology Program, Perlmutter Cancer Center at NYU Langone Health

Join to view full profile

Dr. Balar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Balar's full profile

Already have an account?

Office
160 East 34th Street
10th Floor
New York, NY 10016
Phone+1 212-731-5820

Fax+1 212-731-5527

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
University of South Florida College of MedicineClass of 2006

Certifications & Licensure

NY State Medical License 2008 - 2023

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
Completed
Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
MRI and Bladder Cancer Chemotherapy Start of enrollment: 2013 Aug 01
Withdrawn
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder Start of enrollment: 2016 Aug 11
Active, not recruiting
Phase 2
Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer Start of enrollment: 2017 Sep 13
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10).
Arlene O Siefker-Radtke, Robert A Huddart, Mehmet A Bilen, Arjun Balar, Daniel Castellano
Urologic Oncology. 2024-10-29
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoin...
Daniel P Petrylak, Scott T Tagawa, Rohit K Jain, Manojkumar Bupathi, Arjun Balar
Journal of Clinical Oncology. 2024-10-10
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer.
Yohann Loriot, Arjun V Balar, Daniel P Petrylak, Arash R Kalebasty, Petros Grivas
Clinical Cancer Research. 2024-08-01

Lectures

Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 stu...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Targeted Oncology - FDA Cracks down on Dangling Accelerated Approvals in 2021, Pathway Is ScrutinizedDecember 20th, 2021
Treatment Considerations for Upper Tract Urothelial Carcinoma - Eugene Pietzak and Arjun BalarJune 16th, 2021
$Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer - Arjun Balar$
Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer - Arjun BalarJune 10th, 2021
Join now to see all